Trial Profile
An Open-Label Study to Assess the Effects of BG00012 on Lymphocyte Subsets in Subjects With Relapsing-Remitting Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics; Registrational
- Acronyms PROCLAIM
- Sponsors Biogen
- 01 May 2020 Results presented at the 72nd Annual Meeting of the American Academy of Neurology
- 01 May 2020 Results presented at the 72nd Annual Meeting of the American Academy of Neurology
- 27 Mar 2019 Inerim analysis within first 6 months of DMF treatment assessing Lymphocyte subset dynamics published in the Neurology